Conference call to be on Wednesday, July 6, 2022, at 5:00 PM ET
![DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine
DILIsym application contributes to approval of new drugs for migraine treatment
![Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)
New 3D structure generation functionality and extensions to the HTPK Simulation Module among the many enhancements
![U.S. FDA Renews Annual DILIsym Software Licenses for 2022](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
U.S. FDA Renews Annual DILIsym Software Licenses for 2022
FDA Renewal Ensures Access for DILIsym Evaluation of Drug Candidate Submissions
![Simulations Plus Successfully Delivers FDA-Funded Project](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Successfully Delivers FDA-Funded Project
Collaboration with the US FDA and Center for Research on Complex Generics to Establish the Suitability of Model-Integrated Evidence to Demonstrate Bioequivalence for Long-Acting Injectables
![Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
Funded partnership with large pharmaceutical company will enhance mechanistic dissolution models for injectable formulations
![Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
Total revenue growth of 13%; Software revenue growth of 25%; Diluted Earnings Per Share (EPS) growth of 40%
Board of Directors announces quarterly dividend of $0.06 per share
![Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
SLP will partner with the University of Pittsburgh and its Liver-on-a-Chip platform
![Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development
![Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call
Conference Call to be on Wednesday, April 6, 2022, at 5:00 PM ET
![Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders
Improving access to treatment in the lives of individuals and families affected by rare diseases
![Simulations Plus Releases MembranePlus™ 3.0](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Releases MembranePlus™ 3.0
New functionality for transdermal products creates a state-of-the-art IVIVE methodology in combination with the GastroPlus TCAT platform
![Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced...
![Simulations Plus to Present at Oppenheimer Annual Healthcare Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at Oppenheimer Annual Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy,
![Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be participating in BTIG’s MedTech
![Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
Collaborative research effort will further enhance the ACAT model to aid scientists in the detailed understanding of local drug disposition in the gastrointestinal tract
![Simulations Plus Enters New Collaboration with Leading Animal Health Company](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Enters New Collaboration with Leading Animal Health Company
Partnership will expand virtual animal models to support veterinary medicine and next-generation alternatives to animal testing